Humacyte, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $5.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that highlight Humacyte’s strategic positioning and growth potential. The company has made significant strides in establishing a foundation for the US Symvess launch, with expectations of gaining commercial traction in the latter half of 2025 and into 2026. A key development supporting this outlook is Humacyte’s recent success in penetrating the Department of Defense (DoD) channel, marked by their first sale of Symvess to a military treatment facility.
Moreover, Humacyte’s access to DoD facilities has been bolstered by the ECAT approval, which opens up opportunities across numerous military and veterans’ healthcare institutions. This approval is anticipated to drive further announcements and sales momentum throughout the year. Additionally, while the company has not provided specific guidance for the second quarter, there is an expectation of a sequential increase in product revenue, reflecting ongoing efforts to secure approvals at various hospital accounts. These factors collectively underpin Jennings’s optimistic outlook on Humacyte’s stock.